Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial

BACKGROUND: The aim was to analyze characteristics that predict remission induction and subsequent loss of remission in patients with moderately active rheumatoid arthritis (RA) who received full-dose combination etanercept plus methotrexate induction therapy followed by reduced-dose etanercept or e...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Arthritis Res Ther
Hlavní autoři: Smolen, Josef S., Szumski, Annette, Koenig, Andrew S., Jones, Thomas V., Marshall, Lisa
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2018
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5771183/
https://ncbi.nlm.nih.gov/pubmed/29338762
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-017-1484-9
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky